Fig 2. Graft survival in study groups and standard of care group.

Patients received induction treatment with Alemtuzumab/Infliximab and long-term tacrolimus (TAC, n = 13) or sirolimus (SIR, n = 7) monotherapy. Standard of care group were patients with same inclusion criteria and from the same time period treated with CNI-based (tacrolimus or cyclosporine, mycophenolate mofetil and steroids) immunosuppression (control, n = 174). Log-rank test for comparison of all three groups (p = 0.172).